Enhanced photodynamic antitumor effect on gastric cancer by a novel photosensitive stealth liposome

Namiki, Yoshihisa; Namiki, Tamami; Date, Masataka; Yanagihara, Kazuyoshi; Yashiro, Masakazu; Takahashi, Hiroshi

doi:10.1016/j.phrs.2003.12.015

Cited by 36 publications

(16 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Incorporation of photosensitizer drugs in stealth liposomes have been shown to remarkably enhance the accumulation of the drugs in tumor tissues, thus avoiding the reported potential life-threatening thrombosis upon intravenous injection of some photosensitizer drugs [93]. In a different study, liposomes incorporating chlorin e6 (Ce6) trimethylester (for photodynamic therapy of cancer) was shown to lower the LC 80 by approximately 53 folds in gastric cancer cells compared to Ce6 sodium salt and caused complete tumor remission in animal with gastric cancer [93].…”

Section: Passive Targetingmentioning

confidence: 99%

“…In a different study, liposomes incorporating chlorin e6 (Ce6) trimethylester (for photodynamic therapy of cancer) was shown to lower the LC 80 by approximately 53 folds in gastric cancer cells compared to Ce6 sodium salt and caused complete tumor remission in animal with gastric cancer [93]. m-PEG lipid micelles incorporating hydrophobic benzoporphyrin derivatives, tetraphenylporphin and pyropheophorbide derivatives have also been investigated for photodynamic therapy of cancer [94][95][96].…”

Section: Passive Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Improvement of drug safety by the use of lipid-based nanocarriers

Lim

Banerjee

Önyüksel

2012

Journal of Controlled Release

261

142

View full text Add to dashboard Cite

Section: Passive Targetingmentioning

confidence: 99%

Section: Passive Targetingmentioning

confidence: 99%

Improvement of drug safety by the use of lipid-based nanocarriers

Lim

Banerjee

Önyüksel

2012

Journal of Controlled Release

261

142

View full text Add to dashboard Cite

“…23,24 Briefly, cells (5.0 3 10 3 well 21 ) were precultured in 96-well plates for 24 hr. After 72 hr culture with various agents, medium was removed, and 100 ll of fresh medium containing 0.5 mM of WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) (DOJIN, Kumamoto, Japan) was added to each well.…”

Section: Wst-8 Cell Viability Assaysmentioning

confidence: 99%

“…27 (Thermo Spectronic, Rochester, NY), as in our previous study. 15,24 The other cationic lipids, Lipofectamine (DOSPA/DOPE), Lipofectamine 2000 (LA2000), DMRIE-C, Cellfectin (TMTPS/DOPE), Lipofectin (DOTMA/DOPE) were purchased from Invitrogen and FuGENE6 was purchased from Roche (Indianapolis, IN).…”

Section: In Vitro Invasion Assaysmentioning

confidence: 99%

Preclinical study of a “tailor-made” combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa™) for disseminated peritoneal scirrhous gastric cancer

Namiki¹,

Namiki²,

Yoshida³

et al. 2005

Int. J. Cancer

View full text Add to dashboard Cite

We evaluated the effect of a ''tailor-made'' chemo-gene therapy in scirrhous gastric cancer (SGC)-bearing nude mice. For this tailormade approach, we first selected gefitinib (epidermal growth factor receptor-tyrosine kinase inhibitor)-sensitive SGC cell lines, and 5/8 cell lines demonstrated various degrees of gefitinib-sensitivity. In the highly gefitinib-sensitive NUGC-4, the biological response to NK4 (HGF antagonist/angiogenesis inhibitor) was examined. Subsequently, the composition of an NK4-expressing ternary complex (cationic lipid/nucleic acid/HMG-1, 2 protein) was optimized for maximum transfection activity in NUGC-4. Finally, mice were peritoneally coinoculated with NUGC-4 and scirrhous-associated gastric fibroblasts, NF22, on day 0. Animal models were orally administrated gefitinib (50 mg/kg/day, on days 7-28), and peritoneally NK4-expressing ternary complex (on days 14, 21 and 28). NK4-expression suppressed the gefitinib-resistance induced by the interaction between fibroblasts and SGC, and eventually, this tailor-made combination synergistically decelerated the disease progression by inhibiting proliferative, angiogenic and antiapoptotic effects in tumor tissues. On day 28, both the hemoglobin concentration (g/dl) (control (n 5 8), 11.9; treated (n 5 8), 17.3; p 5 0.0014) and the numbers of mice in good condition (control, 2; treated, 8; p 5 0.0012) were significantly greater, and the abdominal girth (mm) (control, 81.1; treated, 70.3; p 5 0.0036) was significantly reduced. The median points of bloody ascite-free survival time (days) (control, 22; treated, 44; p < 0.0001) and time to euthanasia (days) (control, 36.5; treated, 56; p < 0.0001) were also significantly prolonged. This combination is a potentially useful approach to the treatment of peritoneal gefitinib-sensitive SGC dissemination. ' 2005 Wiley-Liss, Inc.

show abstract

“…On the other hand, the hydrophobicity of the cell membrane can hinder the approach of the ionized PS toward the cells (Temizel et al 2014). All these obstacles are responsible for the special attention given by the scientific community to the PSs cell distribution by different vehicles (Calixto et al 2016, Chen et al 2005, Dragicevic-Curic et al 2009, Namiki et al 2004. Common approaches used for the formulation of PSs are based on the encapsulation of the photosensitizing agent in colloidal carriers, such as oil-based dispersions (Allémann et al 1997, Biolo et al 1996, Chen et al 2005, Feofanov et al 2002, Wöhrle et al 1999 et al 1995, 1996, Konan et al 2003, Stevens et al 2004, and also on the conjugation of the PS with hydrophilic polymers such as polyethylene glycol (PEG) (Brasseur et al 1999, Fehr et al 2000, Hamblin et al 2001 or polylysine (Hamblin et al 1999, Silva et al 2006, Soukos et al 1997.…”

Section: The Drug Delivery Systems In Pdt Of Cancermentioning

confidence: 99%

An insight on the role of photosensitizer nanocarriers for Photodynamic Therapy

Mesquita

Dias

Gamelas

et al. 2018

An. Acad. Bras. Ciênc.

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a modality of cancer treatment in which tumor cells are destroyed by reactive oxygen species (ROS) produced by photosensitizers following its activation with visible or near infrared light. The PDT success is dependent on different factors namely on the efficiency of the photosensitizer deliver and targeting ability. In this review a special attention will be given to the role of some drug delivery systems to improve the efficiency of tetrapyrrolic photosensitizers to this type of treatment.

show abstract

Enhanced photodynamic antitumor effect on gastric cancer by a novel photosensitive stealth liposome

Cited by 36 publications

References 17 publications

Improvement of drug safety by the use of lipid-based nanocarriers

Improvement of drug safety by the use of lipid-based nanocarriers

Preclinical study of a “tailor-made” combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa™) for disseminated peritoneal scirrhous gastric cancer

An insight on the role of photosensitizer nanocarriers for Photodynamic Therapy

Contact Info

Product

Resources

About